Y-mAbs Therapeutics (YMAB) Tops Q4 EPS by 19c, provides guidance

Y-mAbs Therapeutics (NASDAQ: YMAB) reported Q4 EPS of ($0.02), $0.19 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $23.4 million versus the consensus estimate of $20.96 million.

Guidance:

Anticipated DANYELZA® net product revenues of between $95 million and $100 million;
Anticipated operating expenses of between $115 million and $120 million;
Anticipated total annual cash burn of between $15 million and $20 million; and
Cash and cash equivalents anticipated to continue to support operations as currently planned into 2027.

For earnings history and earnings-related data on Y-mAbs Therapeutics (YMAB) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• RH (RH) Tops Q1 EPS by 12c
• Dollarama Inc. (DOL:CN) (DLMAF) PT Raised to Cdn$221 at BMO Capital